NADROPARIN: 676 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
676
Total FAERS Reports
57 (8.4%)
Deaths Reported
355
Hospitalizations
676
As Primary/Secondary Suspect
64
Life-Threatening
22
Disabilities
Active Ingredient: NADROPARIN CALCIUM ·
First Report: 20010226 · Latest Report: 20250509
What Are the Most Common NADROPARIN Side Effects?
#1 Most Reported
Foetal exposure during pregnancy
81 reports (12.0%)
#2 Most Reported
Off label use
77 reports (11.4%)
#3 Most Reported
Premature baby
73 reports (10.8%)
All NADROPARIN Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Foetal exposure during pregnancy | 81 | 12.0% | 5 | 21 |
| Off label use | 77 | 11.4% | 17 | 44 |
| Premature baby | 73 | 10.8% | 3 | 30 |
| Maternal exposure during pregnancy | 72 | 10.7% | 1 | 25 |
| Drug ineffective | 54 | 8.0% | 3 | 25 |
| Sepsis | 46 | 6.8% | 0 | 45 |
| Dyspnoea | 44 | 6.5% | 2 | 29 |
| Fall | 43 | 6.4% | 0 | 42 |
| Exposure during pregnancy | 42 | 6.2% | 0 | 5 |
| Confusional state | 40 | 5.9% | 19 | 26 |
| Diarrhoea | 34 | 5.0% | 0 | 27 |
| Hypertension | 34 | 5.0% | 19 | 19 |
| Premature delivery | 34 | 5.0% | 0 | 7 |
| Thrombocytopenia | 33 | 4.9% | 4 | 28 |
| Platelet count decreased | 32 | 4.7% | 0 | 30 |
| Low birth weight baby | 31 | 4.6% | 3 | 18 |
| Oedema peripheral | 29 | 4.3% | 0 | 26 |
| Product use in unapproved indication | 29 | 4.3% | 2 | 21 |
| Pulmonary embolism | 27 | 4.0% | 5 | 18 |
| Condition aggravated | 25 | 3.7% | 2 | 13 |
Who Reports NADROPARIN Side Effects? Age & Gender Data
Gender: 58.5% female, 41.5% male. Average age: 56.3 years. Most reports from: IT. View detailed demographics →
Is NADROPARIN Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2001 | 15 | 0 | 15 |
| 2002 | 2 | 0 | 2 |
| 2006 | 9 | 0 | 9 |
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 0 |
| 2012 | 6 | 0 | 4 |
| 2013 | 7 | 1 | 3 |
| 2014 | 46 | 3 | 42 |
| 2015 | 30 | 3 | 23 |
| 2016 | 47 | 4 | 30 |
| 2017 | 21 | 2 | 8 |
| 2018 | 39 | 3 | 25 |
| 2019 | 40 | 1 | 23 |
| 2020 | 52 | 22 | 27 |
| 2021 | 13 | 0 | 6 |
| 2022 | 12 | 0 | 9 |
| 2023 | 16 | 0 | 1 |
| 2024 | 11 | 0 | 6 |
| 2025 | 2 | 0 | 2 |
What Is NADROPARIN Used For?
| Indication | Reports |
|---|---|
| Product used for unknown indication | 251 |
| Thrombosis prophylaxis | 79 |
| Anticoagulant therapy | 51 |
| Prophylaxis | 38 |
| Covid-19 | 23 |
| Deep vein thrombosis | 19 |
| Venous thrombosis limb | 19 |
| Pulmonary embolism | 17 |
| Foetal exposure during pregnancy | 16 |
| Thrombosis | 15 |
NADROPARIN vs Alternatives: Which Is Safer?
NADROPARIN vs NAFARELIN
NADROPARIN vs NAFCILLIN
NADROPARIN vs NAFCILLIN\NAFCILLIN
NADROPARIN vs NAFRONYL
NADROPARIN vs NAFTIFINE
NADROPARIN vs NAGLAZYME
NADROPARIN vs NALBUPHINE
NADROPARIN vs NALDEMEDINE
NADROPARIN vs NALMEFENE
NADROPARIN vs NALOXEGOL OXALATE
Official FDA Label for NADROPARIN
Official prescribing information from the FDA-approved drug label.